» Articles » PMID: 17319941

Distinct Mechanisms of Loss of IFN-gamma Mediated HLA Class I Inducibility in Two Melanoma Cell Lines

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2007 Feb 27
PMID 17319941
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The inability of cancer cells to present antigen on the cell surface via MHC class I molecules is one of the mechanisms by which tumor cells evade anti-tumor immunity. Alterations of Jak-STAT components of interferon (IFN)-mediated signaling can contribute to the mechanism of cell resistance to IFN, leading to lack of MHC class I inducibility. Hence, the identification of IFN-gamma-resistant tumors may have prognostic and/or therapeutic relevance. In the present study, we investigated a mechanism of MHC class I inducibility in response to IFN-gamma treatment in human melanoma cell lines.

Methods: Basal and IFN-induced expression of HLA class I antigens was analyzed by means of indirect immunofluorescence flow cytometry, Western Blot, RT-PCR, and quantitative real-time RT-PCR (TaqMan(R) Gene Expression Assays). In demethylation studies cells were cultured with 5-aza-2'-deoxycytidine. Electrophoretic Mobility Shift Assay (EMSA) was used to assay whether IRF-1 promoter binding activity is induced in IFN-gamma-treated cells.

Results: Altered IFN-gamma mediated HLA-class I induction was observed in two melanoma cells lines (ESTDAB-004 and ESTDAB-159) out of 57 studied, while treatment of these two cell lines with IFN-alpha led to normal induction of HLA class I antigen expression. Examination of STAT-1 in ESTDAB-004 after IFN-gamma treatment demonstrated that the STAT-1 protein was expressed but not phosphorylated. Interestingly, IFN-alpha treatment induced normal STAT-1 phosphorylation and HLA class I expression. In contrast, the absence of response to IFN-gamma in ESTDAB-159 was found to be associated with alterations in downstream components of the IFN-gamma signaling pathway.

Conclusion: We observed two distinct mechanisms of loss of IFN-gamma inducibility of HLA class I antigens in two melanoma cell lines. Our findings suggest that loss of HLA class I induction in ESTDAB-004 cells results from a defect in the earliest steps of the IFN-gamma signaling pathway due to absence of STAT-1 tyrosine-phosphorylation, while absence of IFN-gamma-mediated HLA class I expression in ESTDAB-159 cells is due to epigenetic blocking of IFN-regulatory factor 1 (IRF-1) transactivation.

Citing Articles

Identification of genetic fingerprint of type I interferon therapy in visceral metastases of melanoma.

Vizkeleti L, Papp O, Doma V, Gil J, Marko-Varga G, Kovacs S Sci Rep. 2024; 14(1):26540.

PMID: 39489756 PMC: 11532416. DOI: 10.1038/s41598-024-77285-x.


AMPKα2 promotes tumor immune escape by inducing CD8+ T-cell exhaustion and CD4+ Treg cell formation in liver hepatocellular carcinoma.

Ouyang Y, Gu Y, Zhang X, Huang Y, Wei X, Tang F BMC Cancer. 2024; 24(1):276.

PMID: 38424484 PMC: 10905944. DOI: 10.1186/s12885-024-12025-y.


Modification of the tumor microenvironment enhances immunity with plasmid gene therapy.

Shi G, Synowiec J, Singh J, Heller R Cancer Gene Ther. 2024; 31(4):641-648.

PMID: 38337037 PMC: 11702831. DOI: 10.1038/s41417-024-00728-0.


Strategies to overcome low MHC-I expression in paediatric and adult tumours.

Guillaume J, Perzolli A, Boes M Immunother Adv. 2024; 4(1):ltad028.

PMID: 38223409 PMC: 10787372. DOI: 10.1093/immadv/ltad028.


Anti-Gene IGF-I Vaccines in Cancer Gene Therapy: A Review of a Case of Glioblastoma.

Trojan A, Lone Y, Briceno I, Trojan J Curr Med Chem. 2023; 31(15):1983-2002.

PMID: 38031775 DOI: 10.2174/0109298673237968231106095141.


References
1.
Teitz T, Wei T, Valentine M, Vanin E, Grenet J, Valentine V . Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med. 2000; 6(5):529-35. DOI: 10.1038/75007. View

2.
Benitez R, Godelaine D, Lopez-Nevot M, Brasseur F, Jimenez P, Marchand M . Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens. 1999; 52(6):520-9. DOI: 10.1111/j.1399-0039.1998.tb03082.x. View

3.
Serrano A, Tanzarella S, Lionello I, Mendez R, Traversari C, Ruiz-Cabello F . Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment. Int J Cancer. 2001; 94(2):243-51. DOI: 10.1002/ijc.1452. View

4.
Belardelli F, Ferrantini M, Proietti E, Kirkwood J . Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002; 13(2):119-34. DOI: 10.1016/s1359-6101(01)00022-3. View

5.
Paschen A, Mendez R, Jimenez P, Sucker A, Ruiz-Cabello F, Song M . Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events. Int J Cancer. 2003; 103(6):759-67. DOI: 10.1002/ijc.10906. View